Collapsed Haplotype Pattern Method for Linkage Analysis of Next-Generation Sequence Data

Gao T. Wang1, §, Di Zhang1, §, Biao Li1, Hang Dai1, Suzanne M. Leal1\*

1Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA

§These authors contribute equally to this work.

\*Correspondence:

Suzanne M. Leal

Department of Molecular and Human Genetics

Baylor College of Medicine

One Baylor Plaza, 700D

Houston, TX 77030

713-798-4011

[sleal@bcm.edu](mailto:sleal@bcm.edu)**Abstract**

Recent advances in next generation sequencing (NGS) make it possible to directly sequence genomes and exomes of individuals with Mendelian diseases and screen sequence data for causal variants. With the reduction in cost of NGS, DNA samples from entire families can be sequenced and linkage analysis can be performed directly using NGS data. Inspired by “burden” tests which are used for complex trait rare variant association studies, we developed the collapsed haplotype pattern (CHP) method for linkage analysis. Using data from several deafness genes we demonstrate that the CHP method is substantially more powerful than analyzing individual variants. Unlike applying NGS data filtering approaches, the CHP method provides statistical evidence of a gene’s involvement in disease etiology and is also less likely to exclude causal variants in presence of phenocopies and/or reduced penetrance. The CHP method was implemented in the SEQLinkage software package which can perform linkage analysis on NGS data or can generate data compatible with many linkage analysis programs, reviving them for use in NGS era.

**Keywords**

Parametric linkage analysis, LOD scores, Mendelian diseases and traits, Next-generation sequence data, Statistical method.**Introduction**

The advent and advance of NGS in recent years has led to the identification of a large number of Mendelian disease genes. The typical approach to identifying Mendelian disease causal variants using either whole genome sequence (WGS) or exome sequence (WES) data is to filter variants in an affected individual or shared by affected family members, excluding those which are found at higher frequencies, e.g. >0.5% in variant databases. Sometimes unaffected family member(s) are also used in the filtering process. While filtering is straightforward and has been successful1, such efforts rely on limited family information, e.g. mode of inheritance, sharing between a subset of family members and information from external resources on variant functional characterizations and frequencies. On the other hand, linkage analysis, which incorporates information on mode of inheritance, penetrance, allele frequencies and genetic map information, remains a powerful tool to localize Mendelian disease loci. As a result, combined SNP array based linkage analysis and sequence based filtering method is becoming popular2. Although it has been shown that analyzing rare single nucleotide variants (SNVs), usually designated as having a minor allele frequency (MAF) <0.5% or 1%, from WES data provides acceptable linkage results, due to low heterozygosity of SNVs and allelic heterogeneity this approach can be less powerful than analysis of SNPs from genotyping arrays3.

Here we describe the collapsed haplotype pattern (CHP) method which was designed to analyze rare variants by constructing markers that have a higher heterozygosity and are more informative for linkage analysis than individual SNVs. Unlike when SNPs are analyzed, the CHP method does not require linkage disequilibrium (LD) pruning to avoid spurious associations4. The CHP method is particularly powerful in the presents of intra- (e.g. compound heterozygotes) and inter-family allelic heterogeneity, a phenomenon commonly observed for Mendelian diseases. When causal variants are missing from samples, the CHP method can still detect linkage due to transmission information retained by other variants. We have developed the SEQLinkage software package implementing the CHP method. Since SEQLinkage can test for linkage heterogeneity and calculate Heterogeneity LOD (HLOD) scores the CHP method remains powerful when there is locus heterogeneity, i.e. the underlying genetic etiology is not due to the same gene/region in all families.

**Materials and Methods**

For the CHP method instead of analyzing each variant separately, multiple variants which form haplotypes within a genetic region, e.g. gene, are analyzed. This is done by constructing a marker which reflects the transmission pattern of the entire region and is numerically compatible with currently available linkage analysis methods and software. These markers incorporate allelic heterogeneity between and within families in a region and often have higher heterozygosity than SNVs, making them more informative and powerful to detect linkage.

To generate regional markers, haplotypes for the region must be obtained for all samples with sequence data. NGS data from family members are first checked for Mendelian errors and variants with Mendelian inconsistencies are removed. An improved version of the Lander-Green algorithm for genetic phasing is applied to reconstruct haplotypes in the pedigrees5. For each pedigree, we first cluster variants on regional haplotypes by “bins”, e.g. LD blocks, and collapse variants in a bin into an indicator variable with values 0 or 1 for having no minor allele or at least one minor allele within the bin, which is similar to collapsing methods for rare variant association analysis6. We then assign each collapsed haplotype a single numeric value so that different patterns of collapsed haplotypes in each pedigree are uniquely represented (Figure 1). The choice of coding for patterns are arbitrary, although we use continuous positive integers and assign a smaller value for collapsed haplotypes having more 0’s than 1’s. The sample haplotypes thus represented can be directly used for parametric linkage analysis with many existing linkage software packages.

For WES data, genes can be used as regional markers. Within each region, commonly used bin size options for variants collapsing are 1) LD based collapsing, which uses estimated LD blocks as bins, 2) complete collapsing, whose bin size equals gene/region length and 3) no collapsing, whose bin size equals one. For regions where recombination events occur within a family, the sub-unit that shows the strongest evidence of linkage among all sub-units created by recombination breakpoints is used as the regional LOD score for the family, so that results from multiple families can be combined.

In order to reconstruct genotypes for family members missing sequence data, linkage analysis requires marker allele frequencies. Frequencies of regional markers generated by CHP method can be derived from minor allele frequencies (MAF) of variants and pair-wise LD between variants. For rare variants with MAF derived from large samples (see Discussion), the minor allele counts can be approximated by a multivariate Poisson distribution with joint probability mass function  where  is expected allele counts for *M* variants and  is the variance-covariance matrix7. The covariance between variants  and  can be computed by  where  is the LD coefficient,  is population MAF and  is the sample size based on which population MAF are estimated. Therefore for a given haplotype pattern the corresponding frequency  can be computed from the probability mass function. When collapsing is applied, MAF for the collapsed unit is given as  by definition. Calculations of haplotype pattern frequencies are based on population MAF of rare variants; but in a given family where only limited haplotypes are observed, haplotype pattern frequency should be adjusted to reflect their relative probability of occurrence in the family. Therefore for haplotypes in a family we normalize the frequencies so they sum to 1. The normalized collapsed haplotype pattern frequencies are then used as the allele frequencies for the corresponding regional genotype markers.

To facilitate linkage analysis using sequence data in VCF format, we developed the SEQLinkage software that uses the Elston-Stewart algorithm as incorporated in FASTLINK8. It provides results in text format and high quality graphical reports for both LOD and HLOD scores. Additionally SEQLinkage supports output of regional genotype data into formats compatible with linkage software such as LINKAGE9 and Merlin10, with which two-point and multipoint parametric linkage analysis can be performed. Additionally MEGA211 format is supported, which can be used to transform data to the required input for a number of linkage programs.

To evaluate performance of our method we performed empirical type I error and power calculations for two-point linkage analysis using data on four non-syndromic hearing impairment (NSHI) genes: two autosomal recessive genes *GJB2* and *SLC26A4*, and two autosomal dominant genes *MYO7A* and *MYH9*. Two-generation pedigrees were simulated, with 3 to 8 offspring in the last generation with the proportions determined by the distribution of number of children per family in the United States in 2012, rescaled so that they sum to 100% (3 children: 69.34%, 4 children: 20.52%, 5 children: 6.84%, 6 children: 2.28%, 7 children 0.76%, 8 children 0.26%). Genotypes are simulated for the four genes based on the variant sites and the corresponding minor allele frequencies in European Americans recorded in the Exome Variant Server (Table S1).

For power evaluations we annotate variants in these four genes using Deafness Variation Database (DVD) and NCBI ClinVar, labelling variants as “causal” if they are so deemed by both databases. Disease status for individuals are determined by genotypes on those causal sites under dominant mode of inheritance for *MYO7A* and *MYH9*, and recessive (compound heterozygotes and homozygotes) for *GJB2* and *SLC26A4*, assuming complete penetrance. Additionally for each mode of inheritance we allow for allelic heterogeneity among families, i.e., the causal variant site in a gene may not be the same for different families. We “ascertain” simulated families having two or more affected offspring for linkage analysis. To introduce locus heterogeneity we sample families having causal variants in one gene but not the other, so that each simulated gene contributes to etiology of only a proportion of families in the entire dataset. We simulate 500 replicates under each different setting of sample size, mode of inheritance, presence of allelic heterogeneity and locus heterogeneity. For each replicate we compute LOD and HLOD scores using the CHP method. For comparison purposes we also analyze SNV markers and perform multipoint linkage analysis, with multipoint linkage analysis being performed using GeneHunter. Power is estimated by  where the denominator is the total number of replicates and the numerator is the number of tests that successfully detected the linkage signal, i.e. LOD score greater than 3.3 or HLOD score greater than 3.6 which provides a genome wide significance level of p<0.0512.

For type I error evaluations we use the same gene sequences and demographic data, yet simulate disease pedigrees under the null, i.e., affection status not due to any of the rare variants in the gene of interest. We consider different genetic architectures under the null including situations when 1) variants in the gene region are in linkage equilibrium, 2) there is complete LD between variants and 3) under the extreme case where there are recombination events within a gene for each meiosis and recombination breakpoints are different across “ascertained” families. Simulating data based upon a realistic θ value, which is small, within a gene region will introduce few or no recombination events within the generated families, therefore this extreme scenario is used to evaluate the effect of recombination events on type I error. Additionally we simulate scenarios when parental genotypes are missing to evaluate type I error when CHP marker frequencies have to be calculated using population MAF and LD estimated from data. Type I errors are computed for cumulative HLOD scores on gene *SLC26A4* across 20 families using 500 replicates.

**Results**

Empirical type I error estimates are constantly zero for all tested scenarios, assuring that there is no inflation of the test statistic in the presence of within-gene recombination, strong inter-marker LD or missing genotype data. Empirical power calculations for several known non-syndromic hearing loss genes using the CHP method as well as for individual SNV are summarized by contour plots (Figures 2). Power analysis based-on LOD and HLOD suggests that CHP is substantially more powerful for all models in the presence of intra- (Figure 2C) and inter-family allelic heterogeneity (Figures 2A–2C). For example to detect linkage with the *SLC26A4* gene using an autosomal recessive model with allelic heterogeneity, i.e. compound heterozygotes, and also with locus heterogeneity of 50%, 12 families are required for the CHP method to achieve a power of 90%, while analyzing individual SNVs requires >50 families to achieve the same power at a genome wide significance level of α=0.05. Additionally, although multipoint linkage analysis is more powerful than analyzing SNVs, the CHP method is considerably more powerful than multipoint linkage analysis (Table S1).

For sequence data, variants are sometimes missing due to the inability to call variants or during quality control, variant calls are removed because of poor quality data. Therefore we also estimated sample size requirements for the CHP method when causal variants are missing from sequence data in a large proportion of families, i.e. 75%. The CHP method can tolerates missing data and is also always more power than the SNV method when data is missing (Table 1).

**Discussion**

For linkage analysis, correct specification of marker allele frequency is crucial for controlling type I error and reducing type II error13. The number of founders with available genotypes in data for linkage analysis might often be too small to obtain a sufficiently accurate allele frequency estimate, thus we recommend the input VCF file be annotated with an external source of MAF information, e.g. 1000 genomes or Exome Variant Server. For some populations MAF information may not be available and frequencies estimated from founders have to be used.

In the context of Mendelian disease mapping it is reasonable to assume that common variants (variants having population MAF>1%) are not directly causal. Therefore analyzing common variants will neither contribute to nor reduce power when causal rare variants are sequenced and haplotypes are directly used as markers. Common variants can be in strong LD with variants in neighboring regions; thus when the CHP method is used to construct the region marker, linkage can be detected even though the region does not harbor any causal variants. Although common variants should not be used when constructing regions markers, we suggest analyzing common variants separately because they can potentially capture additional information when rare causal variants are missing from sequence data.

Analysis of rare variants using “burden” methods are usually limited to those variants which are most likely to be causal, e.g. missense, nonsense, splice site and frameshift variants, because inclusion of non-causal variants can attenuate the association signal and reduce power. For the CHP methods inclusion of non-causal rare variants will not attenuate the linkage signal and therefore analysis does not need to be restricted to variants which are most likely functional and causal. Inclusion of non-causal rare variants to construct the region marker can provide additional linkage information if data for causal variants are missing. If the goal is to detect a linkage signal from variants which are potentially causal then linkage analysis using the CHP method can be limited to those variant sites which are most likely functional.

In addition to the CHP method being more powerful than performing multipoint linkage analysis, it controls type I error when there is missing parental genotype data and inter-marker LD, which is not the case for multipoint linkage analysis. Caution should be used when performing multipoint linkage analysis on sequence data, since when parental genotypes are missing for some samples (common for NGS based family data) linked variants can lead to serve inflated type I error when markers are assumed to be in linkage equilibrium15,16. The majority of multipoint linkage analysis programs e.g. GeneHunter, SuperLink, Vitesse, do not take into consideration LD between marker loci. Even for linkage programs that can model inter-marker LD, e.g., LINKAGE/FASTLINK and Merlin, the haplotype frequency estimates involving rare variants can be inaccurate for studies with limited number of founders, leading to inflated type I error.

The SEQLinkage package, freely available at URL <http://bioinformatics.org/seqlink>, can efficiently extract genotypes from VCF files and uses the CHP method described here to perform linkage analysis as well as data format conversion on sequence data so that other programs can also be used to perform linkage analysis if desired. It provides a novel and effective approach that brings back well established linkage analysis techniques for use with the growing wealth of genomic data of human pedigrees. Unlike filtering approaches which are commonly used to analyze sequence data, SEQLinkage provides statistical evidence of the involvement of variants in the etiology of Mendelian diseases. Additionally because it incorporates mode of inheritance information and penetrance models it is less likely than filtering approaches to exclude causal variants in the presence of phenocopies and/or reduced penetrance. For Mendelian traits for which the penetrance model is not well established but the mode of inheritance is known, an affected-only analysis can be performed where all unaffected individuals are made unknown to avoid decreased power due the use of an incorrect penetrance model. We recommend the use of SEQLinkage in parallel to filtering methods on the same sequence data to take full advantage of the power of NGS in families.**Acknowledgements**

The authors would like to thank Regie Lyn Santos-Cortez, Daniel Weeks, Alejandro Schaffer, Jeffrey O’Connell and Jurg Ott for helpful discussions and support. This work is funded by National Institute of Health (DC003594, DC011651 and HG006493).

*Conflict of Interest: none declared.*

**References**

1 Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM *et al.* Exome sequencing identifies the cause of a mendelian disorder. *Nat Genet* 2010; **42**: 30–35.

2 Santos-Cortez RLP, Lee K, Azeem Z, Antonellis PJ, Pollock LM, Khan S *et al.* Mutations in KARS, Encoding Lysyl-tRNA Synthetase, Cause Autosomal-Recessive Nonsyndromic Hearing Impairment DFNB89. *Am J Hum Genet* 2013; **93**: 132–140.

3 Smith KR, Bromhead CJ, Hildebrand MS, Shearer AE, Lockhart PJ, Najmabadi H *et al.* Reducing the exome search space for Mendelian diseases using genetic linkage analysis of exome genotypes. *Genome Biol* 2011; **12**: R85.

4 Huang Q, Shete S, Amos CI. Ignoring linkage disequilibrium among tightly linked markers induces false-positive evidence of linkage for affected sib pair analysis. *Am J Hum Genet* 2004; **75**: 1106–1112.

5 Abecasis GR, Wigginton JE. Handling Marker-Marker Linkage Disequilibrium: Pedigree Analysis with Clustered Markers. *Am J Hum Genet* 2005; **77**: 754–767.

6 Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet* 2008; **83**: 311–321.

7 Karlis D. An EM algorithm for multivariate Poisson distribution and related models. *J Appl Stat* 2003; **30**: 63–77.

8 Cottingham RW Jr, Idury RM, Schäffer AA. Faster sequential genetic linkage computations. *Am J Hum Genet* 1993; **53**: 252–263.

9 Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. *Proc Natl Acad Sci* 1984; **81**: 3443–3446.

10 Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet* 2002; **30**: 97–101.

11 Mukhopadhyay N, Almasy L, Schroeder M, Mulvihill WP, Weeks DE. Mega2: data-handling for facilitating genetic linkage and association analyses. *Bioinformatics* 2005; **21**: 2556–2557.

12 Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. *Nat Genet* 1995; **11**: 241–247.

13 Freimer NB, Sandkuijl LA, Blower SM. Incorrect specification of marker allele frequencies: effects on linkage analysis. *Am J Hum Genet* 1993; **52**: 1102–1110.

14 Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. *Am J Hum Genet* 1996; **58**: 1347–1363.

15 Huang Q, Shete S, Swartz M, Amos CI. Examining the effect of linkage disequilibrium on multipoint linkage analysis. *BMC Genet* 2005; **6**: S83.

16 Li B, Leal SM. Ignoring Intermarker Linkage Disequilibrium Induces False-Positive Evidence of Linkage for Consanguineous Pedigrees when Genotype Data Is Missing for Any Pedigree Member. *Hum Hered* 2008; **65**: 199–208.

**Web Resources**

America's Families and Living Arrangements, https://www.census.gov/prod/2013pubs/p20-570.pdf

Exome Variant Server (EVS), http://evs.gs.washington.edu/EVS

Deafness Variation Database (DVD), http://deafnessvariationdatabase.com

NCBI ClinVar, https://www.ncbi.nlm.nih.gov/clinvar

**Figure legends**

**Figure 1. Coding of regional markers using the Collapsed Haplotype Pattern (CHP) method**. Three two-generational autosomal recessive pedigrees display the coding for a region marker using information from 6 variant sites. Panel A shows two families segregating the same autosomal recessive disease which is due to different causal variants. Treating the entire region as a bin to collapse the variants effectively captures transmission of disease variants and allows for linkage information for a region to be combined across families. For regions with more diverse rare variant architecture as displayed in Panel B, where for this example disease etiology is caused by compound heterozygotes variants, coding which represents both rare variant haplotypes is used to ensure that all meioses are informative. It should be noted that if coding as is shown in Panel A is used in this situation there will be a loss of information because all heterozygous offspring will be uninformative for linkage information, e.g. the meioses to offspring 1 and 4.

**Figure 2. Power comparisons for LOD and HLOD statistics in two-point linkage analyses.** This figure shows the power for collapsed haplotype pattern markers (CHP) vs. single nucleotide variant (SNV) analysis under various modes of inheritance in the presence of intra- and inter-family allelic heterogeneity. X-axis is number of families, Y-axis is proportion of locus heterogeneity, i.e. the proportion of families with non-syndromic hearing impairment (NSHI) caused by detrimental variants in the gene under investigation, i.e. either *MYO7A* or *MYH9* for dominant model, or *GJB2* or *SLC26A4* for recessive model. Contour curves on the graphs are power estimates, dark orange lines for the CHP method and light blue lines for SNV analysis. Panel A displays the power for the LOD and HLOD statistics under an autosomal dominant model; panel B displays the power for the LOD and HLOD statistics under an autosomal recessive model; panel C displays the power for the LOD and HLOD statistics under an autosomal recessive model in the presence of intra-family allelic heterogeneity, i.e. affected individuals are compound heterozygous. CHP method is more powerful for both LOD and HLOD at a genome-wide significance level of α=0.05, but the absolute power of HLOD is not significantly larger than LOD. This is due to the very low MAFs for the genes under study and therefore for most families all variants in the non-causal gene are monomorphic and therefore are uninformative.

**Tables**

**Table 1: Sample size estimates for the simulated nonsyndromic hearing impairment study.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Required Power | Gene | MOI | CHP1 | SNV2 | | CHP-M75%3 | | SNV-M75% |
| 0.8 | *SLC26A4* | recessive | 11 | 40 | 39 | | 160 | |
| 0.9 | *SLC26A4* | recessive | 13 | 45 | 46 | | 180 | |
| 0.8 | *SLC26A4* | compound recessive | 11 | 50 | 39 | | 200 | |
| 0.9 | *SLC26A4* | compound recessive | 13 | 55 | 46 | | 220 | |
| 0.8 | *GJB2* | recessive | 12 | 23 | 44 | | 92 | |
| 0.9 | *GJB2* | recessive | 14 | 28 | 52 | | 112 | |
| 0.8 | *GJB2* | compound recessive | 12 | 25 | 44 | | 100 | |
| 0.9 | *GJB2* | compound recessive | 14 | 34 | 52 | | 136 | |
| 0.8 | *MYO7A* | dominant | 12 | 16 | 31 | | 64 | |
| 0.9 | *MYO7A* | dominant | 14 | 20 | 36 | | 80 | |
| 0.8 | *MYH9* | dominant | 11 | 13 | 32 | | 52 | |
| 0.9 | *MYH9* | dominant | 14 | 18 | 41 | | 72 | |
| Note: 50% locus heterogeneity is assumed for all scenarios.  1Number of families required for CHP method.  2Number of families required for single variant method.  3“M-75%”: number of families required when causal variants in 75% participating families are missing. | | | | | | | | |